
    
      The RTOG 8501 has established concurrent radiochemotherapy as the standard of care for cancer
      of the esophagus.However, locoregional remain problematic, with 25% of patients having
      persistence and 20% relapse of locoregional disease following the combined modality approach.
      New regimen is urgently needed for improving localregional control and survival.
    
  